- Home
- PCRX vs ASIC Comparison
PCRX vs ASIC Comparison
Compare PCRX & ASIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- ASIC
- Stock Information
- Founded
- PCRX 2006
- ASIC 2018
- Country
- PCRX United States
- ASIC United States
- Employees
- PCRX N/A
- ASIC N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- ASIC Property-Casualty Insurers
- Sector
- PCRX Health Care
- ASIC Finance
- Exchange
- PCRX Nasdaq
- ASIC Nasdaq
- Market Cap
- PCRX 1.2B
- ASIC 1.1B
- IPO Year
- PCRX 2011
- ASIC 2025
- Fundamental
- Price
- PCRX $22.76
- ASIC $17.59
- Analyst Decision
- PCRX Buy
- ASIC Strong Buy
- Analyst Count
- PCRX 5
- ASIC 4
- Target Price
- PCRX $32.40
- ASIC $25.50
- AVG Volume (30 Days)
- PCRX 479.4K
- ASIC 263.5K
- Earning Date
- PCRX 11-05-2025
- ASIC 10-22-2025
- Dividend Yield
- PCRX N/A
- ASIC N/A
- EPS Growth
- PCRX N/A
- ASIC N/A
- EPS
- PCRX N/A
- ASIC 0.15
- Revenue
- PCRX $705,848,000.00
- ASIC $378,302,000.00
- Revenue This Year
- PCRX $7.36
- ASIC $16.14
- Revenue Next Year
- PCRX $10.07
- ASIC $47.06
- P/E Ratio
- PCRX N/A
- ASIC $115.17
- Revenue Growth
- PCRX 2.25
- ASIC 42.48
- 52 Week Low
- PCRX $16.00
- ASIC $16.35
- 52 Week High
- PCRX $27.64
- ASIC $25.30
- Technical
- Relative Strength Index (RSI)
- PCRX 35.28
- ASIC N/A
- Support Level
- PCRX $24.31
- ASIC N/A
- Resistance Level
- PCRX $26.05
- ASIC N/A
- Average True Range (ATR)
- PCRX 0.82
- ASIC 0.00
- MACD
- PCRX -0.20
- ASIC 0.00
- Stochastic Oscillator
- PCRX 18.36
- ASIC 0.00
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About ASIC Ategrity Specialty Insurance Company Holdings Common Stock
Ategrity Specialty Insurance Co Holdings Formerly Ategrity Specialty Holdings LLC is a specialty insurance company dedicated to providing excess and surplus products to small to medium-sized businesses across the United States. It offers property and casualty insurance solutions tailored to meet the needs of SMBs. The company focuses on are Real Estate, Hospitality, Construction, and Retail.